ArticleMolecules (Basel, Switzerland)2022
Structural Characterization of Polysaccharide Derived from
Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 32 citations in OpenAlex.
- The Influence of Monosaccharide Composition on the Bioactivity of Medicinal Plant Polysaccharides.International journal of molecular sciences · 2026Review
- Transcriptome Analysis Reveals the Immunoregulatory Effect of Two Polysaccharides fromFoods (Basel, Switzerland) · 2026Article
- Molecular-weight fractionation, preliminary structural characterization, bioactivity, and ICP-MS-based biodistribution ofFrontiers in nutrition · 2026Article
- Optimization of the process of acetylation and carboxymethylation for a polysaccharide from Gastrodia elata and antioxidant and immunomodulatory activities test.Scientific reports · 2025Article
- Extraction, Purification, Structural Characteristics, Biological Activities, and Applications of Polysaccharides fromMolecules (Basel, Switzerland) · 2025Review
- Integrated transcriptome and metabolome provide insight into phenolics and soluble sugar variation in the different varieties ofFrontiers in plant science · 2025Article
- Alcoholic brain injury is a modifiable risk factor: natural active substance intervention promises to improve alcohol-induced cognitive impairment.Frontiers in nutrition · 2025Review
- ExploringPolymers · 2024Article
- Tea for histamine anti-allergy: component analysis of tea extracts and potential mechanism for treating histamine anti-allergy.Frontiers in pharmacology · 2024Article
- Comparative analysis of antioxidant activity and structural changes ofFrontiers in nutrition · 2024Article
- Research progress ofFrontiers in chemistry · 2024Review
- In Vitro Neurotrophic Properties and Structural Characterization of a New Polysaccharide LTC-1 fromMolecules (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
A polysaccharide from Gastrodia elata (named GEP-1) was isolated with a DEAE-52 column and Sephadex G-100 column. The structural characteristics showed that GEP-1 was mainly composed of glucose (92.04%), galactose (4.79%) and arabinose (2.19%) with a molecular weight of 76.444 kDa. The polydispersity (Mw/Mn) of GEP-1 was 1.25, indicating that the distribution of molar mass (Mw) was relatively narrow, which suggested that GEP-1 was a homogeneous polysaccharide. Moreover, the molecular conformation plot of the root mean square (RMS) radius (<rg2> 1/2) versus Mw yielded a line with a slope less than 0.33 (0.15 ± 0.02), displaying that GEP-1 is a compact and curly spherical molecule in NaNO3 aqueous solution. NMR and methylation analyses revealed that the main chain structure of GEP-1 was α-(1→4)-glucans. Furthermore, it was proven that GEP-1 possessed cytoproliferative and enhancing phagocytic activities and induced cytokine (TNF-α, IL1-β) and nitric oxide (NO) release in macrophages by upregulating the related gene expression. In addition, the RNA-seq results suggested that the GEP-1-induced immunomodulatory effect was mainly caused by activation of the NF-κB signaling pathway, which was further verified by NF-κB ELISA and pathway inhibition assays. As a result, GEP-1 exhibits the potential to be developed as a novel cheap immunostimulant without obvious toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.